Pharmatest - Pre-Clinical Treatment Efficacy Testing

Pharmatest is a Finnish Contract Research Organisation (CRO) for pre-clinical treatment efficacy testing, located in Turku, Finland. The company was founded in 1999 and operates from facilities which include fully equipped in vitro research laboratories and ex vivo research facilities designed specifically for bone research. Also, we have access to full-service, barrier-type animal facilities.

Pharmtest has offices in Oulu, Finland and our international marketing unit is located in Berlin, Germany. Our key personnel have several years of experience in bone research. Our staff's expertise in bone biology gives us a unique insight to various bone disorders. All of our services have been perfected and validated, and many of them fully developed in-house.

PRE-CLINICAL DRUG EFFICACY TESTING

Our services include unique in vitro efficacy assays, bone analysis services and animal models of osteoporosis, cancer bone metastasis and osteoarthritis. Most of these services have been developed and validated completely in-house.

Pharmatest is dedicated to innovative and high-quality research and we have been collaborating with various pharmaceutical companies to develop new therapies against diseases such as osteoporosis, cancer-induced bone disease, and osteoarthritis for nearly a decade.

We can help you reach your goal faster, increase your profitability, and reduce your fixed costs and financial risks.

IN VITRO BONE CELL EFFICACY ASSAYS

Our services are designed specifically for pharmaceutical companies developing drugs for osteoporosis, cancer-induced bone disease and osteoarthritis, but they are equally useful for companies developing functional foods or ingredients for nutraceuticals with indication on bone health.

Our unique in vitro bone cell efficacy assays, including bone resorption assays for antiresorptive compounds and bone formation assays for anabolic compounds, are specifically designed for osteoporosis drug testing.

These bone cell assays are perfect tools for selecting most potent drug candidates for further testing in our animal models. They also provide an ideal way to test new compounds against cancer-induced bone disease in a cost-effective in vitro setting.

These in vitro services are complimented by our wide selection of in vivo models, such as osteoporosis animal models; including rat ovariectomy and orchidectomy models, as well as a glucocorticoid-induced mouse osteoporosis model.

Following is a brief summary of the different types of services provided by Pharmatest:

• In vitro bone cell efficacy assays (bone resorption and bone formation assay)
• Animal models of primary osteoporosis (rat OVX and ORX model)
• Animal models of secondary osteoporosis
• Systemic cancer bone metastasis models for cancer drug testing
• Osteoarthritis animal model
• Bone analysis services (including histology, histomorphometric analysis, biomechanical testing, BMD and biochemical markers)

RAT OVX MODEL TESTING

All projects are performed according to highest quality standards, and we guarantee that the results we give to you are always obtained with assays that perform as expected. Furthermore, FDA and EMEA guidelines state that any therapeutic agent for postmenopausal osteoporosis must be tested in the rat OVX model before it can obtain approval from FDA and EMEA.

Our rat OVX model can be performed according to FDA / EMEA guidelines, allowing the use of the results directly in the drug approval process. Results from our efficacy models have also been used as such in patent application processes and our results have been successfully reproduced in early clinical trials.